UCLA researchers in the Department of Bioengineering and Department of Chemistry & Biochemistry have developed a novel method for the introduction of various functional groups onto recombinant elastin-like polypeptides (ELPs), creating new compositions of ELPs that may be used for medical therapeutic or diagnostic applications.
Recombinant elastin-like polypeptides (ELPs) belong to a unique class of precision polymers with stimuli-responsive self-assembly properties for specific biomedical and biotechnological applications. ELPs are repeating sequences of [-Val-Pro-Gly-Xaa-Gly-] pentapeptide, where Xaa can be any amino acid except proline. ELPs exhibit a lower critical solution temperature (LCST), meaning ELP chains switch between fully soluble state and insoluble state in water when the temperature is below or above the LCST. Fully reversible solubility switch of ELPs is influenced by parameters such as the Xaa residue within the ELP repeats, the overall molecular weight, molar concentration of the ELP, and the ionic strength of the solution. The controlled self-assembly of individual ELP blocks has been explored to develop nanocarriers for drug-delivery systems. Tuning the LCST of temperature-responsive recombinant ELPs is usually achieved by designing different protein sequences, in terms of amino acid composition and length, implying tedious molecular cloning steps. Post-polymerization modifications of are mostly limited to conjugation of small organic molecules, oligonucleotides, drugs, or PEG to chain ends of ELPs. Modifications at the amino acid side chains within the ELP domain require modification of all the repeating functional groups in these sequences in high yield without affecting the amino acid backbone, C- and N-terminus, and side chain groups of other residues. This approach could be quite challenging for recombinant polypeptides, as it requires the incorporation of non-canonical amino acids.
Researchers at UCLA have developed a novel method for introduction of various functional groups onto recombinant proteins by chemoselective alkylation of methionine. This method can be used to modify elastin repeat side chains and modulate the LCST of the polypeptides.
|United States Of America||Issued Patent||10,526,396||01/07/2020||2015-607|
|European Patent Office||Published Application||3328882||06/06/2018||2015-607|
elastin, elastin-like polypeptides, ELPs, lower critical solution temperature, LCST, recombinant protein modification, side-chain modification, chemoselective, drug delivery, drug carrier, therapeutics, protein scaffold, regenerative medicine